Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
917 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04300647 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer(SKYSCRAPER-04) | completed | Phase 2 | 172 | Hoffmann-La RocheINDUSTRY | 17 | Mar 12, 2026 | clinicaltrials |
| NCT03322267 | Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence | completed | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 |
| Mar 6, 2026 |
| clinicaltrials |
| NCT05218499 | Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | completed | Phase 2 / Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 22 | Mar 2, 2026 | clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT07039162 | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 45 | Ming-Yu LienOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 334 | TakedaINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT05280470 | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)(IDeate-Lung01) | active not recruiting | Phase 2 | 187 | Daiichi SankyoINDUSTRY | 8 | Feb 25, 2026 | clinicaltrials |
| NCT04059484 | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer(AMEERA-3) | terminated | Phase 2 | 367 | SanofiINDUSTRY | 23 | Feb 24, 2026 | clinicaltrials |
| NCT04172675 | A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) | completed | Phase 2 | 107 | Janssen Research & Development, LLCINDUSTRY | 17 | Feb 24, 2026 | clinicaltrials |
| NCT05005442 | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) | completed | Phase 2 | 192 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Feb 19, 2026 | clinicaltrials |
| NCT06829199 | A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) | withdrawn | Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT03332017 | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma(ROSEWOOD) | completed | Phase 2 | 217 | BeiGeneINDUSTRY | 17 | Feb 18, 2026 | clinicaltrials |
| NCT06483334 | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Feb 18, 2026 | clinicaltrials |
| NCT05014412 | A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment(MagnetisMM-9) | completed | Phase 2 | 86 | PfizerINDUSTRY | 4 | Feb 10, 2026 | clinicaltrials |
| NCT02917993 | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Incyte CorporationINDUSTRY | 4 | Feb 9, 2026 | clinicaltrials |
| NCT02747004 | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer(Next MONARCH 1) | active not recruiting | Phase 2 | 234 | Eli Lilly and CompanyINDUSTRY | 14 | Feb 6, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | terminated | Phase 1 / Phase 2 | 272 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 16 | Jan 29, 2026 | clinicaltrials |
| NCT03974022 | Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | active not recruiting | Phase 1 / Phase 2 | 315 | Dizal PharmaceuticalsINDUSTRY | 13 | Jan 29, 2026 | clinicaltrials |
| NCT06764355 | Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma(NICE-ESCC) | recruiting | Phase 2 | 50 | National Taiwan University HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06921837 | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer | recruiting | Phase 1 / Phase 2 | 122 | Bolt Biotherapeutics, Inc.INDUSTRY | 3 | Jan 27, 2026 | clinicaltrials |
| NCT01897480 | A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations(Balise) | completed | Phase 2 | 168 | Eli Lilly and CompanyINDUSTRY | 9 | Jan 26, 2026 | clinicaltrials |
| NCT04744831 | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer(DESTINY-CRC02) | completed | Phase 2 | 122 | Daiichi SankyoINDUSTRY | 10 | Jan 14, 2026 | clinicaltrials |
| NCT03056755 | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments(BYLieve) | completed | Phase 2 | 383 | Novartis PharmaceuticalsINDUSTRY | 19 | Jan 13, 2026 | clinicaltrials |
| NCT04150029 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy(STIMULUS-AML1) | terminated | Phase 2 | 90 | Novartis PharmaceuticalsINDUSTRY | 10 | Jan 13, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT07333976 | o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer | completed | Phase 2 | 90 | Tri-Service General Hospital (TSGH)OTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04585815 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | terminated | Phase 1 / Phase 2 | 34 | PfizerINDUSTRY | 4 | Jan 9, 2026 | clinicaltrials |
| NCT04567615 | A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | completed | Phase 2 | 266 | Bristol-Myers SquibbINDUSTRY | 17 | Jan 8, 2026 | clinicaltrials |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | completed | Phase 2 | 47 | Revolution Medicines, Inc.INDUSTRY | 10 | Jan 6, 2026 | clinicaltrials |
| NCT07124117 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | OBI Pharma, IncINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03443492 | SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer(Pancreas) | completed | Phase 2 | 130 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT03600233 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | active not recruiting | Phase 2 | 34 | TaiRx, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT02854436 | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies(Galahad) | completed | Phase 2 | 289 | Janssen Research & Development, LLCINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT06730009 | Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients | recruiting | Phase 1 / Phase 2 | 42 | Medigen Biotechnology CorporationINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03774082 | Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant(REACH 5) | completed | Phase 2 | 46 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 11, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06632717 | Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 24 | National Taiwan University HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248020 | A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue(BCMRECRAD) | not yet recruiting | Phase 2 | 72 | Chang Gung Memorial HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07244705 | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | recruiting | Phase 1 / Phase 2 | 66 | Anbogen Therapeutics, Inc.INDUSTRY | 2 | Nov 24, 2025 | clinicaltrials |
| NCT04644237 | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)(DESTINY-LUNG02) | completed | Phase 2 | 152 | Daiichi SankyoINDUSTRY | 10 | Nov 21, 2025 | clinicaltrials |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 862 | DualityBio Inc.INDUSTRY | 4 | Nov 21, 2025 | clinicaltrials |
| NCT07055594 | A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors(NbTAST-01) | recruiting | Phase 1 / Phase 2 | 76 | Shine-On Biomedical Co., Ltd.INDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials